MDS 2023 | Relevance of IPSS-R for risk stratification in patients with MDS who undergo SCT
Fernando Barroso Duarte, MD, Federal University of Ceara, Clinical Hospital, Fortaleza, Brazil, discusses the relevance of the Revised International Prognostic Scoring System (IPSS-R) for patients with myelodysplastic syndromes (MDS) who undergo stem cell transplantation (SCT). Prof. Barroso Duarte shares results from a study of patients who underwent SCT in Latin America, where the infrastructure to collect molecular data for the molecular IPSS (IPSS-M) is often unavailable. Prof. Barroso Duarte explains that risk stratification using the IPSS-R can still influence outcomes in SCT candidates, particularly in terms of overall survival (OS). This interview took place at the 17th International Congress on Myelodysplastic Syndromes 2023 (MDS 2023) held in Marseille, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
